Effectiveness and Safety Profiles of Biological Therapies in Inflammatory Bowel Disease: Real Life Data from an Active Pharmacovigilance Project
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effectiveness and Safety Profiles of Biological Therapies in Inflammatory Bowel Disease: Real Life Data from an Active Pharmacovigilance Project
Authors
Keywords
-
Journal
Biomedicines
Volume 10, Issue 12, Pages 3280
Publisher
MDPI AG
Online
2022-12-19
DOI
10.3390/biomedicines10123280
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Risk of infections with ustekinumab and tofacitinib compared to tumor necrosis factor α antagonists in inflammatory bowel diseases
- (2022) David Cheng et al. Clinical Gastroenterology and Hepatology
- Clinical Manifestations of Leukocytoclastic Vasculitis, Treatment, and Outcome in Patients with Ulcerative Colitis: A Systematic Review of the Literature
- (2022) Ivana Pantic et al. Journal of Clinical Medicine
- Incident Colorectal Cancer in Inflammatory Bowel Disease
- (2022) Benedetto Neri et al. Cancers
- Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland
- (2022) Kathrin Perrig et al. Therapeutic Advances in Gastroenterology
- Treatment persistence and maintenance dose titration among ulcerative colitis patients on biologics: a pooled study of three United States claim databases
- (2022) Janvi Sah et al. CURRENT MEDICAL RESEARCH AND OPINION
- Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database
- (2022) Maria Antonietta Barbieri et al. Frontiers in Pharmacology
- Model-Based Meta-Analysis on the Efficacy of Biologics and Small Targeted Molecules for Crohn’s Disease
- (2022) Boran Yu et al. Frontiers in Immunology
- Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis
- (2022) Laurent Peyrin-Biroulet et al. BMC GASTROENTEROLOGY
- Leaky Gut in IBD: Intestinal Barrier–Gut Microbiota Interaction
- (2022) Shunying Yu et al. JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY
- Population-based incidence and prevalence of inflammatory bowel diseases in Milan (Northern Italy), and estimates for Italy
- (2021) Emanuele Crocetti et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- The burden of inflammatory bowel disease in Europe in 2020
- (2021) Mirabella Zhao et al. Journal of Crohns & Colitis
- Cutaneous Manifestations in Biological-Treated Inflammatory Bowel Disease Patients: A Narrative Review
- (2021) Jo L. W. Lambert et al. Journal of Clinical Medicine
- An Update for Pharmacologists on New Treatment Options for Inflammatory Bowel Disease: The Clinicians’ Perspective
- (2021) Carsten Schmidt et al. Frontiers in Pharmacology
- Novel and Emerging Therapies for Inflammatory Bowel Disease
- (2021) Badr Al-Bawardy et al. Frontiers in Pharmacology
- Superior treatment persistence with ustekinumab in Crohn’s disease and vedolizumab in ulcerative colitis compared with anti‐TNF biological agents: real‐world registry data from the Persistence Australian National IBD Cohort (PANIC) study
- (2021) Yanna Ko et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients with Inflammatory Bowel Diseases
- (2021) Siddharth Singh et al. DIGESTIVE DISEASES AND SCIENCES
- Swapping Versus Dose Optimization in Patients Losing Response to Adalimumab With Adequate Drug Levels
- (2021) Xavier Roblin et al. INFLAMMATORY BOWEL DISEASES
- Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database
- (2021) Maria Antonietta Barbieri et al. Drugs - Real World Outcomes
- Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases – a Danish nationwide cohort study
- (2021) Mirabella Zhao et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis
- (2021) Juan S Lasa et al. Lancet Gastroenterology & Hepatology
- Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis
- (2021) Siddharth Singh et al. Lancet Gastroenterology & Hepatology
- Gender Differences in Inflammatory Bowel Disease
- (2020) Thomas Greuter et al. DIGESTION
- Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study
- (2020) Maria Antonietta Barbieri et al. Journal of Clinical Medicine
- Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart review
- (2020) Ulf Helwig et al. BMC GASTROENTEROLOGY
- Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy
- (2020) Roberta Roberti et al. CURRENT MEDICAL RESEARCH AND OPINION
- Vedolizumab or TNF-antagonist use and risk of new or recurrent cancer in patients with inflammatory bowel disease with prior malignancy: A retrospective cohort study
- (2020) Amar Vedamurthy et al. Clinical Gastroenterology and Hepatology
- Treat to target: The role of histologic healing in inflammatory bowel diseases: A systematic review and meta-analysis
- (2020) Akshita Gupta et al. Clinical Gastroenterology and Hepatology
- Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies
- (2020) William J Sandborn et al. INFLAMMATORY BOWEL DISEASES
- Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients
- (2020) Marisa Iborra et al. Scientific Reports
- Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy
- (2019) Chao Chen et al. INFLAMMATORY BOWEL DISEASES
- Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients with Inflammatory Bowel Diseases: a Systematic Review and Meta-analysis
- (2019) Siddharth Singh et al. Clinical Gastroenterology and Hepatology
- Leaky gut: mechanisms, measurement and clinical implications in humans
- (2019) Michael Camilleri GUT
- Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases
- (2019) Ariela Holmer et al. Expert Review of Clinical Immunology
- Persistence with Biologic Treatment in Patients with Inflammatory Bowel Disease: A German Claims Data Analysis
- (2019) Antje Mevius et al. DIGESTION
- Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study
- (2019) Yoon Suk Jung et al. DIGESTIVE DISEASES AND SCIENCES
- A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease
- (2019) Qingdong Guan Journal of Immunology Research
- Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study
- (2018) Anna Viola et al. DIGESTIVE AND LIVER DISEASE
- A Practical Guide to the Safety and Monitoring of New IBD Therapies
- (2018) Benjamin Click et al. INFLAMMATORY BOWEL DISEASES
- Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis
- (2017) Carlos Taxonera et al. INFLAMMATORY BOWEL DISEASES
- Treatment Persistence for Infliximab Versus Adalimumab in Crohnʼs Disease
- (2017) Pablo Olivera et al. INFLAMMATORY BOWEL DISEASES
- Sex Is Associated with Adalimumab Side Effects and Drug Survival in Patients with Crohnʼs Disease
- (2017) Mitchell R. K. L. Lie et al. INFLAMMATORY BOWEL DISEASES
- Vedolizumab as Induction and Maintenance Therapy for Crohnʼs Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy
- (2017) Bruce E. Sands et al. INFLAMMATORY BOWEL DISEASES
- Factors Predicting the Adherence to the Therapy of Italian IBD Patients
- (2017) Cristina Bucci et al. Gastroenterology Research and Practice
- Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational Study
- (2017) Cristina Scavone et al. Frontiers in Pharmacology
- A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn’s Disease Treated with Adalimumab or Infliximab
- (2016) Kaoru Yokoyama et al. ADVANCES IN THERAPY
- Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study
- (2016) A. Stallmach et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Biological therapy increases the health-related quality of life in patients with inflammatory bowel disease in a clinical setting
- (2016) Anne Sofie Krogh Holdam et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies
- (2015) Vito Annese et al. Journal of Crohns & Colitis
- The global burden of IBD: from 2015 to 2025
- (2015) Gilaad G. Kaplan Nature Reviews Gastroenterology & Hepatology
- Cancers Complicating Inflammatory Bowel Disease
- (2015) Laurent Beaugerie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
- (2014) J.F. Rahier et al. Journal of Crohns & Colitis
- Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2013) William J. Sandborn et al. GASTROENTEROLOGY
- Adherence to Anti-TNF Therapy in Inflammatory Bowel Diseases
- (2013) Anthony Lopez et al. INFLAMMATORY BOWEL DISEASES
- Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease
- (2013) Asit Parikh et al. INFLAMMATORY BOWEL DISEASES
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started